Lily Caruso runs the desk's screen through it: a launching cancer drug whose CEO keeps buying his own stock with lunch money he doesn't need to spend, a vaccine binary the entire retail internet is crowded into, a written-off DNA-medicine company with a real date on a real calendar, and the quiet art of the second trip to the FDA. Plus the one sentence about position sizing that matters more than every paragraph around it.* **By Lily Caruso · Tuesday, August 25, 2026 — TrendyVest Deep Analysis** --- A confession before we start: biotech is the sector that taught me humility, and it charged tuition. Years ago — different desk, different life — I watched a company's drug produce data so beautiful the conference room actually applauded, and the stock finished that week down 40% because the beautiful data belonged to a market three sizes smaller than the imagination that had been priced in.
I think about that room every time someone asks me, as a reader did this week, some version of: *which small biotechs would you buy?* So here is my honest answer, in the only form this desk gives it: not a buy list — nobody here is your advisor, and this corner of the market can vaporize 70% of a position before your coffee cools — but the screen itself. The framework, the four names it surfaced this week, the odds we'd hang on each, and the rule that outranks all of it. What you do with a screen is your business.
Showing the work is ours. **The framework, because in biotech the framework is the edge.** This desk's whole season has been about one statute — the tape grades results against the crowd's imagination, not against the chart — and nowhere is that law more absolute than here. So the screen weighs five things, in order. A *dated* catalyst, first and always, because undated stories are how biotech bleeds you: hope has no expiration, and that's precisely the problem.
Second, the base rate for that catalyst's *species* — and the species matter enormously: FDA approval decisions at the PDUFA stage historically pass 85 to 90% of the time; drugs on their second trip after a rejection letter pass even more often; Phase 3 readouts in hard diseases are closer to coin flips; and therapeutic cancer vaccines — hold this one — have spent thirty years failing Phase 3 after gorgeous Phase 2s. Third: what the crowd knows versus what it hasn't priced, because a catalyst everyone is camped on pays less than the same catalyst nobody attends. Fourth, cash — a great readout with three months of runway is just a dilution announcement in a party hat.
Fifth, the tape's own tells: insider money and where the stock sits against its levels. And above the whole screen, in letters large enough to read from the cheap seats: **in binary biotech, position size is the thesis.** The correct size for a readout you cannot truly handicap is small enough that a minus-70% morning changes nothing about your week. I'll say it again at the end.
It will still be the most important sentence on the page. **The first name the screen likes is the boring one, which is usually the tell — Kura Oncology, about $1.1 billion.** Kura's menin inhibitor for a genetically defined slice of acute myeloid leukemia isn't a promise anymore; it's a product. KOMZIFTI is approved, launching, and — here's the number that matters — already taking *a majority of new patient starts* in its niche, with $9.1 million on the board in its early quarter. A majority of new starts is what winning looks like at the very beginning, before the revenue line has had time to say so.
But the detail I keep returning to, the one most of the market hasn't metabolized: the chief executive bought 100,000 shares on the open market on August 17, and then — apparently unsatisfied — another 100,000 on August 24. That's about $2.2 million of personal, after-tax money, at prices within pennies of today's, in eight days. Executives sell for a hundred reasons and buy for one.
Fifteen analysts sit at Strong Buy with a $32 average target against a $13 stock; the tape is basing after doubling in a year. The desk's handicap: roughly 65% the launch narrative holds through year-end, with a clean falsifier — one sequential decline in new patient starts and the story goes back to the shop. The wart, stated plainly: $9.1 million is a seedling, and those price targets assume it becomes a tree without a single bad season. **The second name is the one your feed is already screaming about, which is exactly why it needs the coldest water — SELLAS Life Sciences, $2.9 billion.** SELLAS is running a Phase 3 called REGAL: a vaccine, aimed at a protein called WT1, trying to keep leukemia patients in remission.
The trial ends when the 80th patient relapses or dies — that's the grim arithmetic of oncology trials — and the company sat at 78 events in the spring. The trigger could fire any week now. The bulls' argument is seductive: events are accruing *slowly*, and slow events mean patients aren't relapsing, which means the drug is working.
Maybe. The published bear case makes the counter-argument the crowd doesn't want to hear — slow events can come from enrollment mix and statistical censoring, nothing to do with the drug — and behind it stands that thirty-year graveyard of cancer vaccines that looked alive until the day they didn't. Meanwhile the stock is up some 930% off its $1.39 low, was a top-trending ticker Monday, carries a beta of 2.49, and sits at $14.33, coiled directly beneath the $15.45–15.88 shelf like it's listening for the announcement.
Cash is fine — $138 million — so this is purely, cleanly about the data. The desk's handicap is 35 to 40% for a cleanly positive readout, and I want to be more honest than the format usually allows: that number is a guess wearing a percent sign. Nobody outside the data monitoring committee knows, and anyone who claims otherwise is selling something.
What I do know is that at $2.9 billion, a great deal of success is already paid for, and the crowd is already in the theater. If any name on this page demands the sizing rule, it's this one: the win could double it; the loss is a crater with your name on it. **The third name is the one the market wrote off, which is where mispriced binaries go to hide — Inovio, with a real date: October 30.** Inovio is a 2021 ghost — a DNA-medicine company most traders left for dead and never revisited. The screen doesn't care about stigma; it cares about the calendar, and the calendar says the FDA decides on INO-3107 by October 30.
The disease it treats — recurrent respiratory papillomatosis — is genuinely awful: growths in the airway, surgery after surgery after surgery, some patients dozens of times. The unmet need is not a slide-deck phrase. The base rate at this stage is 85 to 90% approval; the desk trims it to 70–75% for the novelty tax, because this would be a first-of-its-kind DNA immunotherapy and regulators get careful around the word *first*.
Two things to check before the date, both checkable: whether an advisory committee gets scheduled (that restructures the odds), and any whisper of label negotiations slipping. And the wart on the other side of approval: a small company has to actually *sell* the thing, and commercialization is its own second binary that arrives the morning after the champagne. **The fourth idea isn't a name — it's a pattern: the second trip to the FDA.** Drugs that were rejected, fixed, and resubmitted approve at some of the highest rates in the industry, for the obvious human reason that companies don't book a second appointment until they can pass the physical. Two are on the calendar now: Telix's brain-tumor imaging agent, September 11 — seventeen days out, the nearest dated catalyst on this page — and Corcept's Cushing's drug, resubmitted in June for December 17.
Neither is a moonshot; both are the steadier species of binary, singles and doubles at 85%-plus handicaps, with the standing caveat that a stock can price its own good odds in advance. For the watchlist behind the watchlist, flagged and not endorsed: Opus Genetics (October 17), PolyPid (November 28, tiny float, verify everything twice), Ultragenyx (September 19). **How a book would actually hold these — principles, never prescriptions.** Structure follows the risk ladder, not the excitement ladder. The launch story can carry genuine size, because its downside is a disappointing quarter, not a disappearing company.
The dated-decision names carry middle weight, sized to shrug off the 10-to-15% failure branch. The pure binary gets the lottery allocation — small enough to lose entirely without a flinch — or gets watched from the sidelines with zero shame, because shame is not a position and the easy money in a $2.9 billion crowd left the building some floors ago. And diversify across *catalyst species*, not just tickers: one launch plus one decision plus one readout is a portfolio; three readouts is a casino with a coat check.
Then the calendar discipline this desk applies to everything it publishes: every name above has a date or a trigger, and when it passes, the thesis is *over* — win, lose, or drift. Holding a spent binary "because it might come back" is how trades become residents. We grade at the print.
That habit transfers. **The honest fine print, at full size, because this sector has teeth.** This is analysis and framework — information, never investment advice, never a recommendation to buy any security. I hold no positions in any of it. The probability estimates are the desk's informed guesses and some of them will be wrong; the base rates are historical industry aggregates, which is a fancy way of saying the past, which is not the future.
PDUFA dates slip — verify every date against the company's own filings before it matters to you. The SELLAS odds especially deserve your suspicion, including of us. And the sizing rule gets its promised encore, because if you remember one sentence let it be this one: in binary biotech, the size of the position *is* the thesis — everything else is commentary.
Years later, I can still see that applauding conference room, and the tape the next morning, which had not been in the room and did not care. That's this sector in one image: the science and the stock are related the way weather and climate are related — connected, eventually, but on different clocks, and the people who confuse them get rained on. Four names.
Four dates. One rule. Size like the downside is real — because in this corner of the market, it always, always is. — Lily **Tickers in play:** KURA · SLS · INO · TLX · CORT · IRD · PYPD · RARE · XBI (sector reference) --- *This is TrendyVest's analysis and opinion — for informational purposes only, not investment advice or a recommendation to buy or sell any security.
We are not financial advisors; small-cap biotech routinely gaps 60–80% overnight on data; no probability estimate herein is better than an informed guess. Sources: SELLAS's REGAL status (78 events at the Q1 update, the 80th-event trigger mechanics, database-lock-then-topline sequence), SLS009's Q4 topline timing, and the $138.3M cash position per the company's Q1 and Q2 2026 releases (Aug 11); the event-accrual bull/bear debate per Seeking Alpha's published bear analysis and TipRanks' retail-attention coverage; SLS quote ($14.33 −7.34% Monday close, $2.89B cap, 52-week $1.39–15.88, beta 2.49, the Alliance Global target raise to $35) per stockanalysis.com; Kura's KOMZIFTI launch metrics ($9.1M quarter, majority of new NPM1-mutant AML patient starts), the CEO's open-market purchases (100,000 shares on Aug 17 and Aug 24, ~$1.11M each), the Strong Buy consensus at $32, and the quote ($12.40 Monday close; $13.60 premarket Aug 25) per stockanalysis.com's earnings and insider coverage; the catalyst calendar (Telix TLX101-Px PDUFA Sep 11, post-resubmission; Ultragenyx UX111 Sep 19; Opus Genetics Oct 17; Inovio INO-3107 BLA decision Oct 30; PolyPid Nov 28; Corcept relacorilant Dec 17, resubmitted June 17 post-CRL) per Merlintrader's and pdufa.bio's trackers, with the standing instruction to verify each date against filings; approval and readout base rates are historical industry aggregates as commonly cited in regulatory research, not predictions. The desk's odds and falsifiers are its own and will be graded honestly if these catalysts resolve during our coverage.
Every quote carries its stamp; the tape was moving at publication. Do your own research.* *Markets. Tech.
The Edge. Research with receipts.*